Your browser doesn't support javascript.
loading
Willingness of people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials.
VanDevanter, D R; Zemanick, E T; Konstan, M W; Ren, C L; Odem-Davis, K; Emerman, I; Young, J; Mayer-Hamblett, N.
Affiliation
  • VanDevanter DR; Case Western Reserve University School of Medicine, Cleveland, OH United States. Electronic address: dutch.vandevanter@gmail.com.
  • Zemanick ET; University of Colorado, Anschutz Medical Campus, Aurora CO United States.
  • Konstan MW; Case Western Reserve University School of Medicine, Cleveland, OH United States; Rainbow Babies and Children's Hospital, Cleveland, OH United States.
  • Ren CL; Children's Hospital of Philadelphia, Philadelphia, PA United States.
  • Odem-Davis K; Seattle Children's Hospital, Seattle, WA United States.
  • Emerman I; Seattle Children's Hospital, Seattle, WA United States.
  • Young J; Seattle Children's Hospital, Seattle, WA United States.
  • Mayer-Hamblett N; Seattle Children's Hospital, Seattle, WA United States; University of Washington, Seattle, WA United States.
J Cyst Fibros ; 22(4): 652-655, 2023 07.
Article in En | MEDLINE | ID: mdl-37100705
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cystic Fibrosis / Anti-Infective Agents Type of study: Clinical_trials Limits: Humans Language: En Journal: J Cyst Fibros Year: 2023 Document type: Article Country of publication: Países Bajos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cystic Fibrosis / Anti-Infective Agents Type of study: Clinical_trials Limits: Humans Language: En Journal: J Cyst Fibros Year: 2023 Document type: Article Country of publication: Países Bajos